Rentschler Biopharma announces largest single investment at its headquarters in Germany

Construction of a new buffer media station in Laupheim

25-Oct-2024 - Rentschler Biopharma SE announced the construction of a new state-of-the-art buffer media station at its company headquarters in Laupheim. The new facility aims to further increase production efficiency and modernize the site, ensuring that the evolving needs of clients and patients are ...

Rentschler Biopharma’s ATMP facility in Stevenage, UK, receives MHRA approval

UK site now set for clinical production of adeno-associated virus (AAV) vectors for gene therapy

14-Sep-2023 - Rentschler Biopharma SE, a leading global contract development and manufacturing organization (CDMO) for biopharmaceuticals, including advanced therapy medicinal products (ATMPs), announced that it has received the cGMP Manufacturing Compliance Certificate, following the successful inspection by ...

Rentschler Biopharma joins forces with Ikarovec to accelerate novel gene therapies

Ikarovec is developing novel gene therapies to treat serious, but common eye diseases

06-Jun-2023 - Rentschler Biopharma SE and Ikarovec, which is developing novel multicistronic gene therapies to treat major ophthalmic indications, announced that the two companies have entered into a collaboration. Under the agreement, Rentschler Biopharma’s ATMP site in Stevenage, UK, will support the ...

After seven years of accelerated growth at Rentschler Biopharma SE under his leadership as CEO, Dr. Frank Mathias to return to the Supervisory Board

Supervisory Board searches for a successor to be CEO

29-Nov-2022 - Rentschler Biopharma SE announced, that following seven years of accelerated growth at Rentschler Biopharma under his leadership as Chief Executive Officer (CEO), Dr. Frank Mathias will return to the company’s Supervisory Board at the end of the fiscal year in March 2023. He will continue to be ...

Rentschler Biopharma breaks ground at new U.S. production site in greater Boston

Multi-product facility to focus on commercial production of complex molecules for U.S.-based clients

16-Aug-2021 - Rentschler Biopharma announced that the company has broken ground at its new production site, adjacent to its existing site in Milford, MA in the greater Boston area. The new Rentschler Biopharma Manufacturing Center US (RBMC US) will add 22,000 square feet of manufacturing cleanroom space and ...

Vetter and Rentschler Biopharma Further Strengthen their Strategic Alliance

30-Apr-2021 - Rentschler Biopharma and Vetter announced that their strategic collaboration has taken key steps forward. The companies have further strengthened the established framework for their alliance and set up a governance structure, as well as implemented guidelines for their joint approach across ...

Rentschler Biopharma entry into cell and gene therapy

Rentschler Biopharma to build new cell and gene therapy capabilities in the UK

15-Feb-2021 - The Cell and Gene Therapy Catapult (CGT Catapult), an independent centre of excellence in innovation advancing the UK's cell and gene therapy industry, and Rentschler Biopharma SE have announced that Rentschler Biopharma will establish their manufacturing capability in Advanced Therapy Medicinal ...

Rentschler Biotechnologie GmbH transforms into European corporation

05-Oct-2017 - Rentschler Biotechnologie GmbH announced that the Company has successfully transitioned into a European corporation (SE) with entry into the German commercial register on October 1, 2017. The Company is operating as Rentschler Biopharma SE with immediate effect. There will be no operational ...

Rentschler Biotechnologie and Rentschler Fill Solutions Announce Strategic Partnership

13-Jun-2017 - Rentschler Biotechnologie GmbH and Rentschler Fill Solutions GmbH announced a strategic partnership to provide new fill and finish facilities and one-stop solutions for biopharmaceutical products to meet the needs of Rentschler Biotechnologie’s clients. Under the terms of the agreement, ...

Rentschler and Leukocare announce strategic alliance and equity investment

06-Feb-2017 - Rentschler Biotechnologie GmbH, Laupheim and Leukocare AG, Martinsried announced a strategic alliance under which Leukocare will become the specialized technology partner and the exclusive formulation developer for Rentschler’s biopharmaceuticals business. Rentschler in return will become the ...